Breast cancer future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 17: | Line 17: | ||
===Cancer vaccines=== | ===Cancer vaccines=== | ||
*Cancer-testis antigens (CTA) as a vaccine target<ref name="pmid29088794">Mirandola L, Pedretti E, Figueroa JA, Chiaramonte R, Colombo M, Chapman C et al. (2017) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=29088794 Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy.] ''Oncotarget'' 8 (43):74378-74390. [http://dx.doi.org/10.18632/oncotarget.20102 DOI:10.18632/oncotarget.20102] PMID: [https://pubmed.gov/29088794 29088794]</ref> | *Cancer-testis antigens (CTA) as a vaccine target<ref name="pmid29088794">Mirandola L, Pedretti E, Figueroa JA, Chiaramonte R, Colombo M, Chapman C et al. (2017) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=29088794 Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy.] ''Oncotarget'' 8 (43):74378-74390. [http://dx.doi.org/10.18632/oncotarget.20102 DOI:10.18632/oncotarget.20102] PMID: [https://pubmed.gov/29088794 29088794]</ref> | ||
*Personalized peptide vaccination (PPV) | *Personalized peptide vaccination (PPV)<ref name="pmid24992895">Takahashi R, Toh U, Iwakuma N, Takenaka M, Otsuka H, Furukawa M et al. (2014) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=24992895 Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients.] ''Breast Cancer Res'' 16 (4):R70. [http://dx.doi.org/10.1186/bcr3685 DOI:10.1186/bcr3685] PMID: [https://pubmed.gov/24992895 24992895]</ref> | ||
*Antigen-presenting cell (APC) and DC-based tumor vaccination | *Antigen-presenting cell (APC) and DC-based tumor vaccination | ||
==Personalized medicine and I-SPY 2 clinical trial== | ==Personalized medicine and I-SPY 2 clinical trial== | ||
Revision as of 19:15, 26 April 2019
Immunotherapeutic interventions
Generally, cancer immunotherapy refers to immune checkpoint inhibitors and cytokines, adoptive cell therapy, and cancer vaccines.
Immune checkpoint inhibitors
Programmed cell death protein 1 (PD-1)
- Programmed cell death protein 1 (PD-1) is an inhibitory immune checkpoint inhibitor that limits T-cell effector function within tissues, and it is expressed on the surfaces of immune effector cells (T-cells, B cells, NK cells, DCs, and many TILs)and has two known ligands, namely, PD-L1 and PD-L2.
- Anti-PD-1 antibodies (Pembrolizumab, JS001, PDR001, and Nivolumab)
- Anti-PD-L1 antibodies (Atezolizumab and Durvalumab)
Anti-CTLA-4 antibodies (Ipilimumab and Tremelimumab)
- Cytotoxic T lymphocyte-associated protein 4 (CTLA-4) is a T-cell inhibitory receptor that is expressed on activated CD8+ T cells and CD4+ regulatory T cells that express CD25 and Foxp3. [1]
- Immune checkpoint inhibitors might be combined with targeted therapy (i.e Vascular endothelial growth factor (VEGF) and EGFR (epidermal growth factor receptor) inhibitors)
Adoptive cell therapy
- Adoptive cell therapy is defined as the induction of anti-tumor immune responses via the isolation of highly active and tumor-specific lymphocytes, such as TILs, cytotoxic T lymphocytes (CTLs), Th cells, NK and DC cells.[2]
- Chimeric antigen receptors T-cell-based therapy
- T cell receptors (TCRs)—engineered T cells
Cancer vaccines
- Cancer-testis antigens (CTA) as a vaccine target[3]
- Personalized peptide vaccination (PPV)[4]
- Antigen-presenting cell (APC) and DC-based tumor vaccination
Personalized medicine and I-SPY 2 clinical trial
- ↑ Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271 (5256):1734-6. PMID: 8596936
- ↑ June CH (2007) Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117 (6):1466-76. DOI:10.1172/JCI32446 PMID: 17549249
- ↑ Mirandola L, Pedretti E, Figueroa JA, Chiaramonte R, Colombo M, Chapman C et al. (2017) Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy. Oncotarget 8 (43):74378-74390. DOI:10.18632/oncotarget.20102 PMID: 29088794
- ↑ Takahashi R, Toh U, Iwakuma N, Takenaka M, Otsuka H, Furukawa M et al. (2014) Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients. Breast Cancer Res 16 (4):R70. DOI:10.1186/bcr3685 PMID: 24992895